JAGX — Jaguar Health, Inc.
Is JAGX overbought or oversold? Here is the current MarketMoodz read.
Jaguar Health, Inc. (JAGX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.39. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.39
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Jaguar Health, Inc. (JAGX) is a microcap commercial-stage biotechnology company with primary revenue tied to crofelemer (Mytesi) and a narrow therapeutic focus. Financial resources appear constrained relative to the investments required to scale commercial adoption and pursue label expansions, making near-term performance sensitive to financing outcomes and partnership activity. Key potential upside drivers include successful indication expansion, improved payer coverage, or strategic partnerships; conversely, dilution risk, limited distribution reach and competitive or regulatory setbacks are principal downside scenarios. Market perception is muted and liquidity is low, so material positive catalysts would likely be needed to move the share price meaningfully higher.
Key factors
- Small-cap commercial footprint with primary revenue dependent on Mytesi (crofelemer) and limited diversification of product revenues
- Modest current revenue and likely constrained cash runway, increasing likelihood of financing/dilution absent material revenue growth or partnership
- Niche therapeutic focus (gastrointestinal/secretory diarrhea) with some clinical and regulatory precedent but limited large-scale commercial adoption to date
- Potential upside from label expansions, new indications, or strategic partnerships/licensing that could broaden market access and revenue streams
- Valuation is depressed, implying upside if near-term catalysts materialize; stock is sensitive to binary clinical, regulatory, or commercial news
- Market environment favors larger pharma and defensive healthcare names, which may limit investor appetite for microcap biotech/commercial-stage names in the near term
Risks
- Cash constraints and need for equity or convertible financings leading to dilution for existing shareholders
- Limited sales scale, distribution reach and payer coverage that could cap revenue growth absent partnership or significant commercial investment
- Competitive pressures from other symptomatic or disease-modifying GI therapies and generics that could reduce pricing or market share
- Regulatory or clinical setbacks for pipeline programs or label-expansion efforts
- Low liquidity and high share-price volatility typical of microcap biotech stocks, complicating entry/exit for investors
- Reimbursement and payer resistance to broader adoption or new indications
- Execution risk around commercialization, marketing investments, and potential partnership negotiations
See today's live rating, score and targets
Members see the live hourly rating for JAGX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.